<DOC>
	<DOCNO>NCT00102414</DOCNO>
	<brief_summary>The primary objective study compare time progressive disease patient treat gemcitabine plus carboplatin versus carboplatin monotherapy . Patients advance epithelial ovarian cancer fail first-line platinum-containing therapy 6 month treatment discontinuation .</brief_summary>
	<brief_title>Gemcitabine Plus Carboplatin Versus Carboplatin Monotherapy Patients With Advanced Ovarian Cancer</brief_title>
	<detailed_description>Carboplatin commonly use treatment ovarian cancer first- second-line therapy . The efficacy gemcitabine ovarian carcinoma research various Phase 2 study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically proven ovarian cancer evidence recurrence progression Failed firstline platinum contain therapy 6 month treatment discontinuation Documented lesion evidence appropriate computerized tomography ( CT ) , magnetic resonance imaging ( MRI ) scan , chest xray , ultrasound . Previous hormonal therapy radiotherapy must terminate least 3 week study drug administration Adequate bone marrow reserve : neutrophil ≥ 1.5 x 10^9/L platelet ≥ 100 x 10^9/L Receiving concomitant cytotoxic antineoplastic treatment . Hormone replacement therapy allow , steroid antiemetic Clinical evidence central nervous system metastasis Active infection Can adequately follow duration study A second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) Use investigational agent 3 week prior inclusion Serious concomitant systematic disorder incompatible study Received one previous chemotherapy regimen prior gemcitabine treatment Patients tumor borderline malignancy Patients estimate GFR ≤ 50 mL/min</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2005</verification_date>
	<keyword>Ovarian cancer</keyword>
	<keyword>Recurrence progression</keyword>
	<keyword>Gemcitabine plus Carboplatin v Carboplatin</keyword>
</DOC>